Dimple Chakravarty

May 10, 2024 | science.org | Catherine Booth |Rónadh Cox |Zhenli Huang |Ravi Iyer |Mandana Mansouri |Dimple Chakravarty | +8 more

Research ArticleIMMUNOLOGYRavi F. Iyer https://orcid.org/0000-0003-2249-266X, Marieke C. Verweij https://orcid.org/0000-0001-6556-8682, [...] , Sujit S.

Sep 6, 2023 | cell.com | Sujit Nair |Dimple Chakravarty |Vaibhav Patel |Nina Bhardwaj

Neoadjuvant trials for GU cancers have a bright future, but there are still many unanswered questions (see Outstanding questions) that need to be addressed. Neoadjuvant trials allow for a quicker evaluation of the efficacy of drugs, and multiple studies investigating the role of novel agents or therapeutic combinations are currently being conducted (Figure 1, Key figure).

Aug 24, 2023 | frontiersin.org | Housheng Hansen |Yafeng Ma |Dimple Chakravarty |Annika Fendler

MainTreatment options for metastatic lesions of prostate cancer (PCa) are limited, and resistance to androgen signalling inhibitors (ASI) is ultimately inevitable (1–3). Detecting aggressive disease while it is still manageable and understanding the underlying biology are clinical imperatives. The standard invasive tissue biopsy procedure for PCa diagnosis poses a risk to the patient (4), is limited in the early stages of disease (5), and is impractical for longitudinal disease monitoring.